Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic ... - PubMed - NCBI

Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic ... - PubMed - NCBI

Ann Oncol. 2018 Apr 4. doi: 10.1093/annonc/mdy115. [Epub ahead of print]

Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

Geffen DB1.

Author information

PMID:

 

29635411

 

DOI:

 

10.1093/annonc/mdy115